ABMD - アビオメド (ABIOMED Inc.) アビオメド

 ABMDのチャート


 ABMDの企業情報

symbol ABMD
会社名 ABIOMED Inc. (アビオメド)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 アビオメッド(Abiomed Inc.)は機械的循環補助装置のプロバイダーであり、心不全患者向けに連続介護を提供する。同社は血流を改善、または心臓ポンプ機能を果たすことによって心臓を休息、治癒、回復させるように設計された製品を開発・製造・販売する。同社の製品は心臓カテーテル検査室で介入治療を行う心臓専門医に利用され、また心臓外科医が行う心臓手術スイートで血管形成術或は心臓外科手術前・中・後、予防的・緊急的に血行力学的補助を必要とする患者を対象に利用されている。平成24年9月、同社は最大6時間の局部的循環補助を提供する製品「Impella CP」が米国食品医薬品局(FDA)から510(k)認可を取得したと発表した。   アビオメドは、米国の医療装置メ―カ―。心不全患者の心臓回復治療に必要な循環補助装置や内蔵型循環補助装置、モニタリング装置を開発、製造、販売する。また、小型心臓ポンプや完全人工心臓の開発を手掛ける。米国内だけでなく、世界各国で製品の販売を行う。本社はマサチュ―セッツ州ダンバ―ス。   Abiomed is a publicly-traded medical devices company that develops and manufactures the circulatory support device Impella, the world’s smallest heart pump. The company is headquartered in Danvers, Massachusetts and has three additional offices, two in Germany in the cities of Berlin and Aachen, and another in Tokyo, Japan. Michael R. Minogue is Chairman, CEO & President of the company, with Dr. Thorsten Siess as Chief Technology Officer, Dr. Chuck Simonton as Chief Medical Officer and Dr. David M. Weber as Chief Operating Officer. According to Bloomberg, the company "engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients". As of 2019, the company had secured five FDA approvals and 715 patents with 622 pending. For fiscal year 2019, Abiomed reported $769.4 million in revenue and reported diluted earnings per share was $5.61 for the year. Abiomed was founded in Danvers, Massachusetts by David M. Lederman in 1981 as Applied Biomedical Corporation. That year, the company commenced the development of an artificial heart. Funded by federal research grants, Lederman partnered with The Texas Heart Institute to develop the AbioCor, a grapefruit-sized electromagnetic device with an internal battery that completely replaces the heart without wires or tubes passing through the skin. In July 2001, AbioCor became the first artificial heart successfully implanted in a patient, where it pumped more than 20 million times. Fourteen of the AbioCor devices were implanted, during clinical trials from 2001 to 2004, with the longest-living recipient surviving 512 days. The AbioCor won FDA approval in 2006 for patients who are near death and do not qualify for a heart transplant.
本社所在地 22 Cherry Hill Drive Danvers MA 01923 USA
代表者氏名 Michael R. Minogue マイケル・R・ミノーグ
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 978-777-5410
設立年月日 29799
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 1143人
url www.abiomed.com
nasdaq_url https://www.nasdaq.com/symbol/abmd
adr_tso
EBITDA EBITDA(百万ドル) 182.30800
終値(lastsale) 399.16
時価総額(marketcap) 17913167185.6
時価総額 時価総額(百万ドル) 17730.07
売上高 売上高(百万ドル) 641.29100
企業価値(EV) 企業価値(EV)(百万ドル) 17369.554
当期純利益 当期純利益(百万ドル) 186.26200
決算概要 決算概要 BRIEF: For the three months ended 30 June 2018 ABIOMED Inc. revenues increased 36% to $180M. Net income increased from $37.4M to $90.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Investment income net increase from $635K to $1.6M (income) Other income (expense) net) increase from $79K to $188K (income).

 ABMDのテクニカル分析


 ABMDのニュース

   Cardiac Assist Devices Market SWOT Analysis by Top Key Players- Terumo Corporation, Medtronic PLC, Abbott Laboratories, Abiomed Inc, Teleflex Incorporated and Others  2021/02/17 20:19:00 OpenPR
A new research report on the global cardiac assist devices market gives readers a complete guide to the market scenario and its forecast for the period 2017-2027. It is an in-depth analysis of the market that includes market size, pricing
   The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping - Stocks News Feed  2021/01/21 13:05:24 Stocks News Feed
Here’s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20) 10X Genomics Inc (NASDAQ: TXG) ABIOMED, Inc. (NASDAQ: ABMD) Aclaris Therapeutics Inc (NASDAQ: ACRS) Adamis Pharmaceuticals Corp(NASDAQ: ADMP) (announced IND submission of Tempol for COVID-19 treatment) Akari Therapeutics PLC (NASDAQ: AKTX)… Read More »The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
   Andrew J. Greenfield Sells 5,000 Shares of Abiomed, Inc. (NASDAQ:ABMD) Stock  2020/12/31 22:42:41 Watchlist News
Abiomed, Inc. (NASDAQ:ABMD) VP Andrew J. Greenfield sold 5,000 shares of the company’s stock in a transaction on Tuesday, December 29th. The shares were sold at an average price of $321.00, for a total transaction of $1,605,000.00. Following the completion of the sale, the vice president now directly owns 26,930 shares of the company’s stock, […]
   Zacks: Brokerages Anticipate Abiomed, Inc. (NASDAQ:ABMD) Will Announce Earnings of $1.11 Per Share  2020/11/18 15:56:55 Transcript Daily
Brokerages expect that Abiomed, Inc. (NASDAQ:ABMD) will announce earnings per share (EPS) of $1.11 for the current quarter, according to Zacks. Four analysts have made estimates for Abiomed’s earnings, with estimates ranging from $1.01 to $1.21. Abiomed also reported earnings of $1.11 per share in the same quarter last year. The firm is scheduled to […]
   Zacks: Analysts Anticipate ABIOMED, Inc. (NASDAQ:ABMD) Will Announce Quarterly Sales of $201.39 Million  2020/10/24 05:00:44 The Lincolnian
Brokerages expect that ABIOMED, Inc. (NASDAQ:ABMD) will announce sales of $201.39 million for the current quarter, Zacks reports. Five analysts have issued estimates for ABIOMED’s earnings, with estimates ranging from $190.93 million to $209.00 million. ABIOMED posted sales of $204.97 million during the same quarter last year, which would indicate a negative year over year […]
   The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping - Stocks News Feed  2021/01/21 13:05:24 Stocks News Feed
Here’s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 20) 10X Genomics Inc (NASDAQ: TXG) ABIOMED, Inc. (NASDAQ: ABMD) Aclaris Therapeutics Inc (NASDAQ: ACRS) Adamis Pharmaceuticals Corp(NASDAQ: ADMP) (announced IND submission of Tempol for COVID-19 treatment) Akari Therapeutics PLC (NASDAQ: AKTX)… Read More »The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
   Andrew J. Greenfield Sells 5,000 Shares of Abiomed, Inc. (NASDAQ:ABMD) Stock  2020/12/31 22:42:41 Watchlist News
Abiomed, Inc. (NASDAQ:ABMD) VP Andrew J. Greenfield sold 5,000 shares of the company’s stock in a transaction on Tuesday, December 29th. The shares were sold at an average price of $321.00, for a total transaction of $1,605,000.00. Following the completion of the sale, the vice president now directly owns 26,930 shares of the company’s stock, […]
   Zacks: Brokerages Anticipate Abiomed, Inc. (NASDAQ:ABMD) Will Announce Earnings of $1.11 Per Share  2020/11/18 15:56:55 Transcript Daily
Brokerages expect that Abiomed, Inc. (NASDAQ:ABMD) will announce earnings per share (EPS) of $1.11 for the current quarter, according to Zacks. Four analysts have made estimates for Abiomed’s earnings, with estimates ranging from $1.01 to $1.21. Abiomed also reported earnings of $1.11 per share in the same quarter last year. The firm is scheduled to […]
   Zacks: Analysts Anticipate ABIOMED, Inc. (NASDAQ:ABMD) Will Announce Quarterly Sales of $201.39 Million  2020/10/24 05:00:44 The Lincolnian
Brokerages expect that ABIOMED, Inc. (NASDAQ:ABMD) will announce sales of $201.39 million for the current quarter, Zacks reports. Five analysts have issued estimates for ABIOMED’s earnings, with estimates ranging from $190.93 million to $209.00 million. ABIOMED posted sales of $204.97 million during the same quarter last year, which would indicate a negative year over year […]
   $201.39 Million in Sales Expected for ABIOMED, Inc. (NASDAQ:ABMD) This Quarter  2020/10/24 01:28:48 Daily Political
Equities research analysts expect that ABIOMED, Inc. (NASDAQ:ABMD) will report $201.39 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for ABIOMED’s earnings, with the highest sales estimate coming in at $209.00 million and the lowest estimate coming in at $190.93 million. ABIOMED posted sales of […]
   Zacks: Brokerages Anticipate Abiomed, Inc. (NASDAQ:ABMD) Will Announce Earnings of $1.11 Per Share  2020/11/18 15:56:55 Transcript Daily
Brokerages expect that Abiomed, Inc. (NASDAQ:ABMD) will announce earnings per share (EPS) of $1.11 for the current quarter, according to Zacks. Four analysts have made estimates for Abiomed’s earnings, with estimates ranging from $1.01 to $1.21. Abiomed also reported earnings of $1.11 per share in the same quarter last year. The firm is scheduled to […]
   Zacks: Analysts Anticipate ABIOMED, Inc. (NASDAQ:ABMD) Will Announce Quarterly Sales of $201.39 Million  2020/10/24 05:00:44 The Lincolnian
Brokerages expect that ABIOMED, Inc. (NASDAQ:ABMD) will announce sales of $201.39 million for the current quarter, Zacks reports. Five analysts have issued estimates for ABIOMED’s earnings, with estimates ranging from $190.93 million to $209.00 million. ABIOMED posted sales of $204.97 million during the same quarter last year, which would indicate a negative year over year […]
   $201.39 Million in Sales Expected for ABIOMED, Inc. (NASDAQ:ABMD) This Quarter  2020/10/24 01:28:48 Daily Political
Equities research analysts expect that ABIOMED, Inc. (NASDAQ:ABMD) will report $201.39 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for ABIOMED’s earnings, with the highest sales estimate coming in at $209.00 million and the lowest estimate coming in at $190.93 million. ABIOMED posted sales of […]
   Zacks: Analysts Anticipate ABIOMED, Inc. (NASDAQ:ABMD) Will Post Quarterly Sales of $201.39 Million  2020/10/24 01:28:47 Daily Political
Equities research analysts expect ABIOMED, Inc. (NASDAQ:ABMD) to post sales of $201.39 million for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for ABIOMED’s earnings, with the lowest sales estimate coming in at $190.93 million and the highest estimate coming in at $209.00 million. ABIOMED posted sales of $204.97 million during the […]
   Short Interest in ABIOMED, Inc. (NASDAQ:ABMD) Rises By 18.4%  2020/10/21 03:46:44 Stock Observer
ABIOMED, Inc. (NASDAQ:ABMD) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 2,570,000 shares, an increase of 18.4% from the September 15th total of 2,170,000 shares. Based on an average daily volume of 324,900 shares, the days-to-cover ratio is presently 7.9 days. Currently, […]

 関連キーワード  (先端医療機器_テクノロジ― 米国株 アビオメド ABMD ABIOMED Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)